SNOA Nasdaq Surgical & Medical Instruments & Apparatus Financials FY2017βFY2026
Sonoma Pharmaceuticals, Inc. had $19.5M of revenue in fiscal 2026, up 36.7% on the year before. Over five years, revenue changed +0.9% a year on average.
Last close Β· Oct 23, 2026
$1.11
3.5%Hi! I read Sonoma Pharmaceuticals, Inc.βs latest annual report (fiscal 2026). Here is what stands out:
Good So-so Weak
Are sales growing?
+36.7%
Yes. Sales grew 36.7% last year.
Does it make a profit?
β16.3%
No. It lost money last year.
Does profit turn into cash?
β21.1%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 9
Weak. It passes 3 of 9 health tests.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days Sonoma Pharmaceuticals, Inc. did it, and the next one. Share prices often move a lot on those days.
Next results
November 3, 2026
Tuesday Β· in 8 days
| Date | Results for | Time | Source |
|---|---|---|---|
| Aug 6, 2026 | Q1 '27 | Before the market opens | 10-Q β |
| Jun 16, 2026 | Q4 '26 | After the market closes | 10-K β |
| Feb 10, 2026 | Q3 '26 | After the market closes | 10-Q β |
| Nov 4, 2025 | Q2 '26 | Before the market opens | 10-Q β |
| Aug 7, 2025 | Q1 '26 | After the market closes | 10-Q β |
| Jun 17, 2025 | Q4 '25 | After the market closes | 10-K β |
| Feb 5, 2025 | Q3 '25 | After the market closes | 10-Q β |
| Nov 7, 2024 | Q2 '25 | Before the market opens | 10-Q β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· Sonoma Pharmaceuticals, Inc. had $19.5M of revenue in fiscal 2026, up 36.7% on the year before. Over five years, revenue changed +0.9% a year on average. Its operating margin was β12.6%, up 13.4Β pts: of every 100 in sales, about β13 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Sonoma Pharmaceuticals, Inc. lost $3.2M in fiscal 2026.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$4.1M in fiscal 2026, β21.1% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
KIRA Β· Sonoma Pharmaceuticals, Inc. has $2.2M more cash than debt.
Cash, debt and the ratios that show how comfortably Sonoma Pharmaceuticals, Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash and short-term investments | $7.4M | $3.8M | $3.1M | $5.4M | $2.4M |
| Debt incl. finance leases | $0.0M | $0.4M | $0.3M | $0.2M | $0.2M |
| Debt / equity | 0.0x | 0.1x | 0.1x | 0.0x | 0.1x |
| Current ratio | 2.8x | 3.7x | 3.4x | 3.1x | 2.5x |
| Quick ratio | 2.4x | 2.9x | 2.6x | 2.4x | 1.7x |
| Total assets | $18.8M | $16.2M | $14.7M | $13.7M | $14.0M |
| Total liabilities | $10.1M | $8.3M | $8.6M | $9.3M | $10.9M |
| Shareholders' equity | $8.7M | $8.0M | $6.1M | $4.4M | $3.1M |
| Net debt (β = net cash) | β$7.4M | β$3.4M | β$2.8M | β$5.2M | β$2.2M |
KIRA Β· Its return on capital was β211.8%: every 100 invested in the business earned about β212 in a year.
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Sonoma Pharmaceuticals, Inc. passes 3 of 9 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 3 / 9 | 3 / 9 | 1 / 9 | 3 / 9 | 3 / 9 | 3 / 9 | 5 / 9 | 5 / 9 | 3 / 9 |
| Accruals ratio | 68.5% | β8.5% | β0.5% | 8.8% | β3.9% | β5.0% | 5.7% | β15.7% | β23.7% | 5.5% |
| Altman Z'' | β11.17 | β23.10 | β37.32 | β38.60 | β36.06 | β29.40 | β34.87 | β40.45 | β44.32 | β44.40 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $12.8M | $16.7M | $19.0M | $17.9M | $18.6M | $12.6M | $13.3M | $12.7M | $14.3M | $19.5M |
| Net interest income | β | β | β | β | $0.0M | β$0.0M | $0.0M | β | β | β |
| Gross profit | $5.7M | $7.3M | $8.9M | $8.1M | $6.6M | $4.0M | $4.5M | $4.7M | $5.5M | $7.4M |
| Research and development | $1.6M | $1.6M | $1.5M | $1.3M | $0.6M | $0.1M | $0.2M | $1.9M | $1.8M | $2.3M |
| Operating income | β$13.0M | β$14.2M | β$11.3M | β$7.4M | β$3.4M | β$5.9M | β$4.6M | β$4.7M | β$3.7M | β$2.5M |
| Interest expense | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | β | β | β | β | β |
| Pretax income | β$12.9M | β$14.3M | β$11.3M | β$3.5M | β$3.9M | β$5.4M | β$5.2M | β$5.0M | β$2.9M | β$3.4M |
| Income tax | β$4.3M | $0.1M | $0.5M | $0.0M | $0.7M | β$0.3M | β$0.0M | β$0.2M | $0.6M | β$0.2M |
| Net income | $9.3M | β$14.3M | β$11.8M | β$3.3M | β$4.0M | β$5.1M | β$5.2M | β$4.8M | β$3.5M | β$3.2M |
| Diluted EPS | $2.20 | β$28.49 | β$12.77 | β$2.24 | β$1.97 | β$1.92 | β$1.52 | β$10.63 | β$2.79 | β$1.89 |
| Diluted shares | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B |
| Cash flow | ||||||||||
| Cash from operations | β$8.2M | β$12.4M | β$11.7M | β$4.6M | β$3.4M | β$4.2M | β$6.2M | β$2.4M | β$0.1M | β$3.9M |
| Capital expenditure | $0.4M | $0.2M | $0.1M | $0.2M | $0.2M | $0.1M | $0.3M | $0.0M | $0.1M | $0.2M |
| Free cash flow | β$8.6M | β$12.6M | β$11.8M | β$4.8M | β$3.6M | β$4.4M | β$6.4M | β$2.4M | β$0.2M | β$4.1M |
| Depreciation and amortization | $0.2M | $0.5M | $0.5M | $0.3M | $0.2M | $0.2M | $0.1M | $0.2M | $0.1M | $0.1M |
| Stock-based compensation | $2.1M | $2.5M | $1.6M | $0.8M | $0.4M | $0.4M | $0.7M | $0.5M | $0.2M | $0.3M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $17.5M | $10.1M | $3.7M | $3.7M | $4.2M | $7.4M | $3.8M | $3.1M | $5.4M | $2.4M |
| Total debt | $0.2M | $0.3M | $0.3M | $0.5M | $1.9M | $0.0M | $0.4M | $0.3M | $0.2M | $0.2M |
| Current assets | $22.6M | $16.3M | $12.5M | $12.3M | $13.0M | $16.4M | $13.8M | $12.5M | $12.6M | $12.1M |
| Current liabilities | $3.3M | $3.3M | $3.6M | $4.7M | $4.1M | $5.8M | $3.7M | $3.7M | $4.1M | $4.8M |
| Inventory | $2.2M | $2.9M | $3.4M | $2.2M | $2.5M | $2.7M | $2.9M | $2.7M | $2.9M | $3.7M |
| Property and equipment, net | $1.2M | $1.1M | $0.7M | $0.4M | $0.4M | $0.3M | $0.5M | $0.4M | $0.2M | $0.3M |
| Total assets | $25.5M | $19.2M | $14.4M | $14.6M | $15.0M | $18.8M | $16.2M | $14.7M | $13.7M | $14.0M |
| Total liabilities | $4.0M | $3.9M | $4.0M | $8.9M | $9.6M | $10.1M | $8.3M | $8.6M | $9.3M | $10.9M |
| Preferred stock | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | $21.4M | $15.3M | $7.8M | $5.6M | $5.4M | $8.7M | $8.0M | $6.1M | $4.4M | $3.1M |
| Margins | ||||||||||
| Gross margin | 44.2% | 43.9% | 46.8% | 45.3% | 35.2% | 31.6% | 33.7% | 37.3% | 38.2% | 38.0% |
| Operating margin | β101.2% | β85.2% | β59.3% | β41.2% | β18.5% | β46.6% | β34.4% | β36.9% | β26.0% | β12.6% |
| EBITDA margin | β99.2% | β82.2% | β57.0% | β39.5% | β17.3% | β45.1% | β33.5% | β35.5% | β25.0% | β11.9% |
| Net margin | 72.3% | β86.0% | β62.2% | β18.5% | β21.2% | β40.3% | β38.8% | β38.0% | β24.2% | β16.3% |
| FCF margin | β66.8% | β75.8% | β62.3% | β26.8% | β19.1% | β34.7% | β48.4% | β18.8% | β1.2% | β21.1% |
| Net interest share of revenue | β | β | β | β | 0.0% | β0.1% | 0.1% | β | β | β |
| Returns | ||||||||||
| Return on capital | β247.5% | β203.0% | β201.4% | β241.8% | β89.4% | β357.5% | β78.7% | β111.5% | β | β211.8% |
| Return on capital employed | β58.5% | β89.0% | β103.7% | β75.2% | β31.6% | β45.2% | β36.5% | β42.7% | β38.7% | β27.0% |
| Return on equity | 43.3% | β78.0% | β102.2% | β49.4% | β71.9% | β72.3% | β61.8% | β68.5% | β65.5% | β84.6% |
| Return on assets | 36.4% | β64.2% | β70.1% | β22.8% | β26.7% | β30.1% | β29.4% | β31.2% | β24.3% | β23.0% |
| Return on tangible equity | 43.3% | β93.5% | β151.8% | β58.8% | β73.7% | β58.5% | β64.6% | β78.8% | β78.4% | β102.6% |
| Growth | ||||||||||
| Revenue growth | β | 29.9% | 13.9% | β5.5% | 3.9% | β32.2% | 5.1% | β4.0% | 12.2% | 36.7% |
| Net income growth | β | β254.5% | β | β | β | β | β | β | β | β |
| EPS growth | β | β1,395.0% | β | β | β | β | β | β | β | β |
| Share count change | β | β88.1% | 83.7% | 59.8% | 35.1% | β99.9% | 125,603.7% | β86.6% | 172.7% | 35.7% |
| Financial health | ||||||||||
| Debt / equity | 0.0x | 0.0x | 0.0x | 0.1x | 0.4x | 0.0x | 0.1x | 0.1x | 0.0x | 0.1x |
| Interest coverage | β4,324.7x | β354.7x | β341.2x | β461.9x | β287.4x | β | β | β | β | β |
| Current ratio | 6.9x | 5.0x | 3.5x | 2.6x | 3.2x | 2.8x | 3.7x | 3.4x | 3.1x | 2.5x |
| Quick ratio | 6.2x | 4.1x | 2.5x | 2.1x | 2.6x | 2.4x | 2.9x | 2.6x | 2.4x | 1.7x |
| Capital allocation | ||||||||||
| Capex / revenue | 3.1% | 1.1% | 0.5% | 1.1% | 1.0% | 1.1% | 2.0% | 0.0% | 0.6% | 1.0% |
| Stock comp / revenue | 16.7% | 15.0% | 8.6% | 4.7% | 2.0% | 3.0% | 5.0% | 4.1% | 1.6% | 1.3% |
| Quality scores | ||||||||||
| Piotroski F-score | β | 3.0 | 3.0 | 1.0 | 3.0 | 3.0 | 3.0 | 5.0 | 5.0 | 3.0 |
| Altman Z'' | β11.2 | β23.1 | β37.3 | β38.6 | β36.1 | β29.4 | β34.9 | β40.4 | β44.3 | β44.4 |
| Accruals ratio | 68.5% | β8.5% | β0.5% | 8.8% | β3.9% | β5.0% | 5.7% | β15.7% | β23.7% | 5.5% |
Source: SEC EDGAR XBRL filings (CIK 0001367083). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
